Oral antiplatelet agent hypersensitivity and cross-reactivity managed by successful desensitisation
10.5415/apallergy.2015.5.1.51
- Author:
Nicholas CHIN
1
;
Kanishka RANGAMUWA
;
Raymond MARIASOOSAI
;
Jonathan CARNES
;
Francis THIEN
Author Information
1. Department of Respiratory Medicine, Eastern Health, Melbourne, Victoria 3128, Australia. drnicholaschin@gmail.com
- Publication Type:Case Report
- Keywords:
Platelet aggregation inhibitors;
Hypersensitivity;
Cross reactions;
Desensitization, immunologic
- MeSH:
Adenosine Diphosphate;
Blood Platelets;
Cardiovascular Diseases;
Cross Reactions;
Desensitization, Immunologic;
Hypersensitivity;
Myocardial Infarction;
Percutaneous Coronary Intervention;
Platelet Aggregation Inhibitors;
Prasugrel Hydrochloride;
Stents;
Thienopyridines;
Thrombosis
- From:
Asia Pacific Allergy
2015;5(1):51-54
- CountryRepublic of Korea
- Language:English
-
Abstract:
Oral platelet aggregation inhibitors are widely used for the treatment and prevention of cardiovascular diseases, including coronary stent thrombosis. Premature discontinuation following percutaneous coronary intervention would pose a grave risk of in-stent thrombosis, acute myocardial infarction and eventual death. Although they share the same mechanism of adenosine diphosphate P2Y12 platelet receptor inhibition, they belong to either the chemical class of thienopyridines (clopidogrel, prasugrel, and ticlopidine) or cyclopentyl-triazolo-pyrimidines (ticagrelor and cangrelor). This case describes the first documented cross-reactive hypersensitivity of clopidogrel towards both its fellow thienopyridine, prasugrel, as well as the structurally dissimilar ticagrelor, and its subsequent successful desensitisation.
